Efficiency of blinatumomab in a t(8;21) acute myeloid leukemia expressing CD19

Adriana Plesa, Hélène Labussière-Wallet, Sandrine Hayette, Gilles Salles, Xavier Thomas, and Pierre Sujobert

Disclosures: Gilles Salles has received financial compensations for participating to advisory boards, consulting, or educational events from: Abbvie, Amgen, Celgene, Gilead, Epizyme, Janssen, Karyopharm, Kite, Merck, Morphosys, Novartis, Roche, Servier, Takeda

Contributions: AP, HLW, SH, GS, XT and PS designed the study, analysed the data and wrote the paper